I Welcome to BIND Therapeutics
BIND Therapeutics
BIND Therapeutics: A new way of targeting disease
BIND: A NANOMEDICINE PLATFORM COMPANY DEVELOPING TARGETED THERAPEUTICS
 
At BIND, we seek to significantly improve patients' lives and treat disease by developing ACCURINS®, our novel targeted and programmable therapeutics.
BIND develops ACCURINS® to outperform conventional drugs by selectively accumulating in diseased tissues and cells.
WHAT ARE ACCURINS®?
 
ACCURINS® are BIND's targeted and programmable therapeutics that are designed, utilizing our MEDICINAL NANOENGINEERING® platform, with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues.
Learn more >
MEDICINAL NANOENGINEERING®
 
We develop ACCURINS® using our proprietary MEDICINAL NANOENGINEERING® platform that enables predictable, rapid design, characterization and optimization of our targeted and programmable nanomedicines.
Learn more >